Literature DB >> 28095078

Diagnosis, classification, and therapeutic interventions for sinopulmonary Aspergillosis.

Matthew William McCarthy1, Daniel Aguilar-Zapata2, Vidmantas Petraitis2, Thomas J Walsh3.   

Abstract

INTRODUCTION: Sinopulmonary aspergillosis represents a diverse collection of allergic, invasive, and chronic sinus and respiratory conditions. These diseases can affect patients with and without immune impairment and in some cases may be life-threatening. Areas covered: We review the diagnosis, classification, and therapeutic options available to treat sinopulmonary aspergillosis and look ahead to emerging diagnostic and therapeutic options that may soon play an important role in clinical practice. Expert commentary: Histopathology and tissue culture remain the gold standard for the diagnosis of invasive sinopulmonary aspergillosis, but several new molecular detection methods have recently emerged, including various PCR-based platforms, MALDI-TOF, and lateral flow assays. We examine these methodologies as well as the barriers associated with the standardization, validation, and implementation. We also explore the pipeline of antifungal agents in development to treat sinopulmonary aspergillosis.

Entities:  

Keywords:  PCR; allergic bronchopulmonary aspergillosis; isavuconazole; lateral flow assay; magnetic resonance; voriconazole

Mesh:

Substances:

Year:  2017        PMID: 28095078     DOI: 10.1080/17476348.2017.1283986

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  3 in total

1.  Isolated cerebral aspergillosis in an immunocompetent woman on treatment for bacterial infected necrotizing pancreatitis: A case report.

Authors:  Shaoyang Zhang; Qinghui Fu; Qi Chen; Ting-Bo Liang
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 2.  Translational Development and Application of (1→3)-β-d-Glucan for Diagnosis and Therapeutic Monitoring of Invasive Mycoses.

Authors:  Matthew W McCarthy; Ruta Petraitiene; Thomas J Walsh
Journal:  Int J Mol Sci       Date:  2017-05-24       Impact factor: 5.923

Review 3.  Pharmacokinetics and Pharmacodynamics of Ibrexafungerp.

Authors:  Matthew William McCarthy
Journal:  Drugs R D       Date:  2021-12-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.